IBM's $10 billion will flow across research and development, capital expenditure, manufacturing expansion, ecosystem partnerships, and mergers and acquisitions.

A Foundry That Changes the Supply Chain The 2029 Target Is More Specific Than It Sounds Government Backing Reshapes the Competitive Landscape However, the market's enthusiasm requires context. As of May 22, 2026, IonQ, Rigetti, and D-Wave carried price-to-sales ratios of 109, 836, and 791, respectively. At those multiples, the market is already pricing in outcomes that remain years away. Meanwhile, IBM's share price rose 3% on May 28, a comparatively muted reaction that reflects its diversified revenue base and the market's familiarity with its quantum narrative. Where the Real Investor Risk Sits IBM's $10 billion will flow across research and development, capital expenditure, manufacturing expansion, ecosystem partnerships, and mergers and acquisitions. That breadth introduces execution risk. Anderon's launch remains subject to the finalization of definitive agreements between IBM and the Department of Commerce under the current letter of intent. The CHIPS grant is still a proposed incentive, not a finalized disbursement. The Bottom Line for Investors However, the most important question is no longer whether IBM builds the best quantum computer. Instead, it is whether Anderon can become the manufacturing layer that the broader U.S. quantum industry depends upon. If that strategy succeeds, IBM could capture value from industry growth regardless of which quantum hardware developer ultimately leads the market.

Physicists at the University of Oxford show they can assemble Schrödinger’s cat-like superpositions from far more exotic quantum ingredients.

Selection marks the next phase of construction on Micron’s New York project, expected to generate 50,000 jobs.

OneAdvanced has launched what it bills as the UK’s first private, sovereign healthcare large language model trained on NHS primary-care data.